H.C. Wainwright Reaffirms Vertex Buy Rating After ADA Conference Results
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best fundamental stocks to buy according to hedge funds. With a price target of $550, H.C.
Vertex Pharmaceuticals Inc / Ma (VRTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 1,171,571 | $568,001,052 | -17% | 0.86% |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 489,667 | $237,400,355 | +135% | 0.44% |
| 3. | Alyeska Investment Group Anand Parekh | 431,804 | $209,347,215 | +457% | 0.83% |
| 4. | Millennium Management Israel Englander | 309,935 | $150,262,687 | -1% | 0.08% |
| 5. | 277,000 | $134,295,140 | -21% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $196.34 | 4,243 | $833,070.62 | 73,754 | 2021-08-19 | Filing | |
| $195.14 | 5,757 | $1,123,420.98 | 69,511 | 2021-08-19 | Filing | |
| $197.91 | 15,000 | $2,968,650.00 | 41,210 | 2021-08-02 | Filing | |
| $218.79 | 3,905 | $854,374.95 | 26,210 | 2020-11-10 | Filing | |
| $217.49 | 4,270 | $928,682.30 | 22,305 | 2020-11-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $424.69 | 52 | $22,083.88 | 23,281 | 2025-05-15 | Filing | |
| $505.86 | 400 | $202,344.00 | 4,831 | 2025-05-02 | Filing | |
| $510.00 | 3,231 | $1,647,810.00 | 23,281 | 2025-03-13 | Filing | |
| $500.00 | 3,298 | $1,649,000.00 | 51,671 | 2025-03-10 | Filing | |
| $499.99 | 3,242 | $1,620,967.58 | 51,239 | 2025-03-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 28,533,308 | $13,833,749,349 | 2.24% | |
| 2. | 23,491,161 | $11,388,984,677 | 0.21% | |
| 3. | 21,782,933 | $10,560,801,400 | 0.22% | |
| 4. | 14,536,344 | $7,047,591,088 | 1.53% | |
| 5. | 11,788,657 | $5,715,376,687 | 0.24% |
News See All
Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Vertex Pharmaceuticals Presents "Unprecedented" Data for T1D Cell Therapy Zimislecel, Shows Durable Benefit
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now.
13 Best Biotech Stocks To Invest In Now
In 2023, the global biotechnology market size was estimated at $1.55 trillion.
Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Vertex Pharmaceuticals (VRTX) Soared as Investors Back Strategic Initiatives
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Large Cap Equity Strategy” first quarter 2025 investor letter.
Vertex Presents New Data on the Benefits of ALYFTREK
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential.
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
Billionaire Hedge Funds
